Pharmaron Beijing Co Ltd
SZSE:300759
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
CN |
Balance Sheet
Balance Sheet Decomposition
Pharmaron Beijing Co Ltd
Pharmaron Beijing Co Ltd
Balance Sheet
Pharmaron Beijing Co Ltd
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
75
|
462
|
294
|
321
|
4 460
|
2 935
|
3 527
|
1 448
|
5 791
|
1 623
|
843
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
2 770
|
0
|
5 791
|
1 623
|
843
|
|
| Cash Equivalents |
75
|
462
|
294
|
321
|
4 460
|
2 935
|
757
|
1 448
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
183
|
910
|
2 634
|
1 308
|
774
|
1 373
|
1 600
|
|
| Total Receivables |
273
|
461
|
645
|
784
|
1 111
|
1 357
|
1 689
|
2 512
|
3 007
|
3 263
|
3 508
|
|
| Accounts Receivables |
249
|
391
|
543
|
655
|
946
|
1 210
|
1 424
|
2 214
|
2 636
|
2 867
|
3 173
|
|
| Other Receivables |
24
|
70
|
102
|
129
|
165
|
147
|
265
|
298
|
371
|
397
|
335
|
|
| Inventory |
48
|
93
|
93
|
120
|
157
|
282
|
680
|
1 041
|
1 013
|
1 117
|
1 472
|
|
| Other Current Assets |
39
|
81
|
46
|
50
|
33
|
57
|
113
|
227
|
289
|
233
|
356
|
|
| Total Current Assets |
435
|
1 097
|
1 078
|
1 275
|
5 944
|
5 540
|
8 644
|
6 536
|
10 874
|
7 608
|
7 778
|
|
| PP&E Net |
501
|
742
|
2 094
|
2 555
|
2 882
|
3 799
|
5 811
|
8 464
|
10 062
|
10 798
|
11 970
|
|
| PP&E Gross |
501
|
742
|
2 094
|
2 555
|
2 882
|
3 799
|
5 811
|
8 464
|
10 062
|
10 798
|
11 970
|
|
| Accumulated Depreciation |
272
|
346
|
476
|
718
|
1 008
|
1 339
|
1 672
|
2 166
|
3 008
|
3 858
|
4 836
|
|
| Intangible Assets |
21
|
22
|
302
|
390
|
421
|
566
|
693
|
803
|
789
|
791
|
1 197
|
|
| Goodwill |
0
|
0
|
134
|
140
|
203
|
1 166
|
2 096
|
2 688
|
2 781
|
2 761
|
3 586
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
24
|
24
|
59
|
|
| Long-Term Investments |
5
|
3
|
49
|
141
|
236
|
446
|
763
|
1 008
|
1 005
|
883
|
1 158
|
|
| Other Long-Term Assets |
212
|
940
|
262
|
299
|
248
|
392
|
383
|
974
|
941
|
1 063
|
1 346
|
|
| Other Assets |
0
|
0
|
134
|
140
|
203
|
1 166
|
2 096
|
2 688
|
2 781
|
2 761
|
3 586
|
|
| Total Assets |
1 175
N/A
|
2 805
+139%
|
3 919
+40%
|
4 801
+23%
|
9 935
+107%
|
11 909
+20%
|
18 389
+54%
|
20 493
+11%
|
26 477
+29%
|
23 927
-10%
|
27 094
+13%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
41
|
61
|
92
|
108
|
118
|
191
|
316
|
406
|
412
|
477
|
607
|
|
| Accrued Liabilities |
88
|
105
|
138
|
211
|
290
|
472
|
626
|
785
|
806
|
882
|
1 073
|
|
| Short-Term Debt |
170
|
211
|
275
|
382
|
214
|
377
|
422
|
663
|
577
|
765
|
1 265
|
|
| Current Portion of Long-Term Debt |
38
|
99
|
197
|
176
|
130
|
93
|
156
|
239
|
336
|
432
|
3 624
|
|
| Other Current Liabilities |
627
|
185
|
240
|
431
|
518
|
848
|
1 463
|
1 819
|
1 524
|
1 668
|
1 795
|
|
| Total Current Liabilities |
965
|
661
|
941
|
1 308
|
1 270
|
1 982
|
2 982
|
3 912
|
3 654
|
4 224
|
8 364
|
|
| Long-Term Debt |
26
|
366
|
893
|
1 044
|
675
|
581
|
4 708
|
5 215
|
8 902
|
4 779
|
2 151
|
|
| Deferred Income Tax |
0
|
0
|
11
|
22
|
41
|
107
|
173
|
261
|
290
|
292
|
397
|
|
| Minority Interest |
0
|
0
|
13
|
13
|
71
|
63
|
166
|
291
|
681
|
604
|
674
|
|
| Other Liabilities |
15
|
14
|
64
|
101
|
112
|
305
|
231
|
264
|
392
|
410
|
443
|
|
| Total Liabilities |
1 006
N/A
|
1 041
+3%
|
1 922
+85%
|
2 488
+29%
|
2 168
-13%
|
3 038
+40%
|
8 260
+172%
|
9 944
+20%
|
13 920
+40%
|
10 308
-26%
|
12 030
+17%
|
|
| Equity | ||||||||||||
| Common Stock |
131
|
591
|
591
|
591
|
794
|
794
|
794
|
1 191
|
1 787
|
1 778
|
1 779
|
|
| Retained Earnings |
70
|
49
|
279
|
602
|
1 078
|
2 131
|
3 554
|
4 574
|
5 818
|
7 257
|
8 568
|
|
| Additional Paid In Capital |
107
|
1 129
|
1 129
|
1 129
|
5 965
|
6 028
|
6 008
|
5 254
|
5 222
|
5 008
|
4 950
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
73
|
45
|
302
|
668
|
463
|
416
|
305
|
|
| Other Equity |
0
|
5
|
1
|
9
|
2
|
38
|
74
|
197
|
194
|
8
|
72
|
|
| Total Equity |
168
N/A
|
1 763
+949%
|
1 998
+13%
|
2 313
+16%
|
7 767
+236%
|
8 870
+14%
|
10 129
+14%
|
10 549
+4%
|
12 557
+19%
|
13 619
+8%
|
15 064
+11%
|
|
| Total Liabilities & Equity |
1 175
N/A
|
2 805
+139%
|
3 919
+40%
|
4 801
+23%
|
9 935
+107%
|
11 909
+20%
|
18 389
+54%
|
20 493
+11%
|
26 477
+29%
|
23 927
-10%
|
27 094
+13%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
131
|
591
|
591
|
591
|
924
|
924
|
1 773
|
1 772
|
1 773
|
1 778
|
1 778
|
|